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esponsibility of InstAbstract The aim of this study was to apply the reference-scaled average bioequivalence (RSABE)
approach to evaluate the bioequivalence of 2 formulations of agomelatine, and to investigate the
pharmacokinetic properties of agomelatine in Chinese healthy male subjects. This was performed in a
single-dose, randomized-sequence, open-label, four-way crossover study with a one-day washout period
between doses. Healthy Chinese males were randomly assigned to receive 25 mg of either the test or
reference formulation. The formulations were considered bioequivalent if 90% conﬁdence intervals (CIs)
for the log-transformed ratios and ratio of geometric means (GMR) of AUC and Cmax of agomelatine were
within the predetermined bioequivalence range based on RSABE method. Results showed that both of the
90% CIs for the log-transformed ratios of AUC and Cmax of 7-desmethyl-agomelatine and 3-hydroxy-
agomelatine were within the predetermined bioequivalence range. The 90% CIs for natural log-
transformed ratios of Cmax, AUC0–t and AUC0–1 of agomelatine (104.42–139.86, 101.33–123.83 and
97.90–117.94) were within the RSABE acceptance limits, and 3-hydroxy-agomelatine (105.55–123.03,
101.95–109.10 and 101.72–108.70) and 7-desmethyl-agomelatine (104.50–125.23, 102.36–111.50 and
101.62–110.64) were within the FDA bioequivalence deﬁnition intervals (0.80–1.25 for AUC and3
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Fang Tang et al.720.75–1.33 for Cmax). The RSABE approach was successful in evaluating the bioequivalence of these two
formulations.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Agomelatine is a novel antidepressant for use in the European
Union1. It is thought to act through a combination of antagonist
activity at serotonin 5-HT2C receptors and agonist activity at
melatonergic MT1/MT2 receptors
2. As such, its pharmacology is
unique among licensed antidepressant drugs. In patients with
major depression, agomelatine is as effective as paroxetine,
setraline, venlafaxine and ﬂuoxetine, with a lower relapse rate
(23.9%) than placebo (50.0%)3,4. Agomelatine improves sleep
quality and reduced waking after sleep onset in depressed
patients5,6. At a therapeutic dose (25 mg once daily)7, agomelatine
preserves vigilance and memory in healthy volunteers8. Due to the
risk of common liver enzyme elevation and rare serious liver
complications, routine laboratory monitoring of liver function is
recommended periodically throughout treatment9.
The existing data on agomelatine metabolism, bioavailability
and pharmacokinetics in Caucasians indicate that the absorption of
agomelatine is rapid, with the median Tmax 0.75–1.5 h and almost
complete with at least 80% intestinal absorption10,11. However, the
absolute oral bioavailability of this drug is low (approximately
3%–4%) and highly variable (estimated to 104%). These proper-
ties are attributed to the extensive ﬁrst pass metabolism of ago-
melatine7.
A systemically active generic drug is considered to be bioequivalent
to the reference-listed drug if the rate and extent of absorption of the
two products do not show a signiﬁcant difference12. The US Food and
Drug Administration (FDA) uses peak drug concentrations (Cmax) in
plasma or other appropriate biological ﬂuid as an index of drug rate of
absorption and the area under the drug plasma concentration versus
time curve (AUC) as an index of a drug's extent of absorption13. Due
to the highly variable features (highly variable drugs are deﬁned as
those for which within-subject variability [CV(%)] in bioequivalence
measures is 30% or greater), a standard number of subjects (e.g.,
18–24) may not be able to demonstrate the bioequivalence of generic
products or their corresponding reference product using a two-way
crossover design. Although agomelatine pilot data are published for
Caucasians, they may not be applicable to the bioequivalence in other
populations due to ethnic differences. Pei et al.14 investigated the intra-
subject CV of agomelatine in healthy Chinese volunteers. Results
showed notable intra-subject variability in AUC0–t (CV¼43.52%) and
Cmax (CV¼78.34%). Wang et al.15 evaluated the inter- and intra-
individual variability in AUC and Cmax of agomelatine tablets in
Chinese healthy male subjects and found inter-individual CVs of Cmax,
AUC0–t and AUC0–1 to be 102.20%, 131.74% and 130.59%,
respectively. The intra-individual CVs of Cmax, AUC0–t and AUC0–1
were 84.34%, 49.61% and 50.83%, respectively. In preliminary
experiments with a four-way crossover method, the within-subjects
variability of AUC and Cmax of agomelatine were 53% and 70%,
respectively. Comparable values for 3-hydroxy-agomelagtine were
21.2% and 37.8%, and for 7-desmethyl-agomelatine were 42.6%
and 61.4%. These results showed that although the within-subject CVof agomelatine could be reduced with a four-way crossover method, it
was still difﬁcult to evaluate the bioequivalence. Song et al.16 found no
differences in agomelatine pharmacokinetics between the rs2069514
GG homozygotes (n¼35) and the rs2069514 AG allele (n¼35) in all
subjects, suggesting that the rs762551, rs2470890 and rs2472304
genetic polymorphisms might be associated with the marked inter-
individual variability of agomelatine.
The topic of bioequivalence evaluation of highly variable drugs is
one that has been intensely debated in many recent articles, conferences
and meetings17. The FDA observed that studies of highly variable
drugs generally used more subjects than studies of lower variability18.
For the highly variable drug agomelatine, excessively large sample
sizes would be required by a standard bioequivalence study, but the
FDA discourages unnecessary human testing. These observations raise
questions about the appropriate sample sizes for bioequivalence studies
of drug products for which high variability does not appear to impact
safety and efﬁcacy. An additional concern is that the large sample sizes
needed for bioequivalence studies of highly variable drugs may deter
the development of new generic products19,20. A ﬁnal concern is that a
highly variable reference product may not be shown to be bioequiva-
lent to itself in a crossover study using a relatively modest number of
subjects (e.g., 18–40)21. The commonly-accepted method for statistical
analysis of bioequivalence data is the average bioequivalence (ABE)
approach. Bioequivalence is established when the difference between
the logarithmic means occur between preset regulatory limits, as shown
below:
μTμR
 2rθA2 ð1Þ
where μT is the population average response of the log-
transformed measure for the test (T) formulation, μR is the
population average response of the log-transformed measure for
the reference (R) formulation, and θA is equal to ln 1.25. So the
limits are:
ln 0:8r μTμR
 
r ln 1:25 ð2Þ
On one hand, only the average means of main pharmacokinetic
parameters (e.g., AUC and Cmax) are taken into consideration in
ABE method, and the individual variations of pharmacokinetic
parameters are not considered. Thus, the two formulations showed
ABE does not guarantee individuals' bioequivalence (IBE). On
another hand, the bioequivalence criteria for the ABE method are
identical for both low variability and high variability drugs.
For a time, the FDA worked toward implementing an individual
bioequivalence (IBE) approach for studies submitted to New Drug
Applications (NDAs) and Abbreviated New Drug Application
(ANDAs, for generic drugs). It was argued that requiring drug
products to meet an IBE rather than an ABE standard would
improve formulation switchability22,23. The proposed criteria for
acceptable IBE included the comparison of test and reference
means, comparison of within-subject variances, assessment
subject-by-formulation interactions, and ability to scale the bioe-
quivalence limits if within-subject variability of the reference
Implementation of a reference-scaled average bioequivalence approach 73product exceeded predetermined values. Under IBE, the inequality
used to determine if two products are bioequivalent is as follows:
μTμR
 2 þ σD2 þ σWT2σWR2 
σWR2
rθI ð3Þ
where σD
2 is the population subject-by-formulation interaction
variance components, σWT
2 is the population within-subject
variance of the test formulation, σWR
2 is the population within-
subject variance of the reference formulation, and θI is the
bioequivalence limit for IBE. From 1999 to 2001, at the FDA's
request, the pharmaceutical industry applied the IBE study design
and analysis to NDAs and ANDAs for modiﬁed-release drug
products24. The IBE was used to evaluate the bioequivalence of
modiﬁed-release drug products because it was thought that, due to
the relative complexity of modiﬁed-release formulations, the
likelihood was greatest of detecting subject-by-formulation inter-
actions with these types of drug products. However, analysis of
these data failed to detect the presence of clinically signiﬁcant
subject-by-formulation interactions25.
To lower the sample size required for bioequivalence studies of
highly variable drugs, the FDA and European Medicines Agency
(EMA) have recommended the RSABE approach, whereby the
bioequivalence acceptance limits are scaled to the variability of a
reference product26,27.
The RSABE for both AUC and Cmax is evaluated as below:
μTμR
 2
σWR2
rθS ð4Þ
where μT is the population average response of the log-
transformed measure for the test (T) formulation, μR is the
population average response of the log-transformed measure for
the reference (R) formulation, and σWR
2 is the population within-
subject variance of the reference formulation, θS ¼ ln1:25ð Þ
2
σW02
is the
bioequivalence limits, and σW02 is a predetermined constant set by
the regulatory agency.
Under this model, the implied limits (which represent FDA's
desired consumer risk model) on μTμR are:
 ln1:25 σWR
σW0
 
rμTμRr ln1:25
σWR
σW0
ð5Þ
If σWR
2¼σW02 , the implied limits are equal to the standard
unscaled bioequivalence limits of 7ln 1.25 (0.80–1.25). If
σWR
24σW0
2, the implied limits are wider than the standard limits.
If σWR
2oσW02, the implied limits are narrower than the standard
limits.
The Agency has determined that it is acceptable for the implied
limits to be wider than the standard limits only when σWR is large
(as for highly variable drugs). The mixed scaling model is as
shown below.
T and R are considered bioequivalent if:
μTμR
 2
σW02
r ln1:25ð Þ
2
σW02
if σWRrσW0 ð6Þ
and if:
μTμR
 2
σWR2
r ln1:25ð Þ
2
σW02
if σWRZσW0 ð7Þ
The FDA sets the value of σW0 at 0.25
26,28.
The FDA implemented RSABE for highly variable generic drug
wide therapeutic index to ease the regulatory burden. In the
RSABE approach recommended by the FDA, the referenceproduct is administered twice in order to determine its within-
subject variability. As such, the bioequivalence study can use
either a partial replicate (three-way crossover: RTR, RRT or TRR)
or full replicate (four-way crossover: RTRT or TRTR) design, but
should enroll a minimum of 24 subjects28,29. The implied
bioequivalence limits scale to reference within-subject variability
once σWR¼σW0¼0.25 or greater. However, to preserve an
acceptable (o5%) type I error rate, applicants cannot apply
reference scaling to calculate bioequivalence limits until the
reference product within-subject SD in the bioequivalence study
is at least 0.294.
Therefore, the aim of this study was to investigate the pharmaco-
kinetic properties of agomaletine and the bioequivalence of a test
agomelatine tablet (Chongqing FuAn Pharmaceutical Group Qingyu-
tang Pharmaceutical Co., Ltd., Chongqing, China; lot No. 130301) and
a reference agomelatine tablet (Servier, French; lot No. 893158) to
obtain regulatory approval for the test formulation. In this study, we
used the RSABE method to evaluate the bioequivalence of two
formulations with parent agomelatine for the ﬁrst time in healthy
Chinese male subjects.2. Materials and methods
2.1. Study design and procedures
A single-dose, randomized-sequence, open-label, four-way crossover
study was conducted at the phase I Clinical Research Unit of the Third
Xiangya Hospital of Central South University (Changsha, China) from
November 2012 to April 2014. The study (Chinese National Registry
Code: 2013L00911) was performed in accordance with the 2008
version of the World Medical Association Declaration of Helsinki30,
the International Conference on Harmonization Guideline for Good
Clinical Practice31, and the local regulatory guidelines of the State
Food and Drug Administration (SFDA) of People's Republic of
China32. The study protocol, protocol amendment, and informed-
consent form were approved by the independent ethics and research
committee at the Third Xiangya Hospital of Central South University
prior to the initiation of the study. Before undergoing any study
procedure, all participants provided written consent after they had been
informed of the study's purpose, nature, procedures, and risks by
clinical investigators.
A computer-generated random number table of SPSS 17.0 was
applied to assign subjects in a ratio of 1:1 to receive a single
25-mg dose of (administered with 250 mL of tap water at room
temperature) either the test or the reference formulation of agomelatine.
Volunteers were admitted into the phase I clinical research unit at
9:00 p.m. the day before study and fasted 10 h before each drug
administration. Neither caffeine-containing nor alcoholic beverages
were allowed until 24 h after dosing. Smoking was forbidden during
the same interval after the dose administration. As the t1/2 of
agomelatine is approximately 1–2 h, a one day washout period was
used following administration of the initial formulation, after which the
alternate formulation was administered. The design scheme of the
study is summarized in Table 1.
2.2. Subjects
Formulations were considered bioequivalent if the 90% CIs for the
log-transformed ratios and ratio of geometric means (GMR) of
AUC and Cmax of agomelatine were within the predetermined
bioequivalence range based on RSABE method. Both the 90% CIs
Table 1 Study design for the bioequivalence evaluation of test and reference agomelatine tablet
formulations.
Study period Group Agomelatine formulation administered
First 1 One tablet (25-mg dose) of agomelatine reference formulation
2 One tablet (25-mg dose) of agomelatine test formulation
One day wash-out period
Second 1 One tablet (25-mg dose) of agomelatine test formulation
2 One tablet (25-mg dose) of agomelatine reference formulation
One day wash-out period
Third 1 One tablet (25-mg dose) of agomelatine reference formulation
2 One tablet (25-mg dose) of agomelatine test formulation
One day wash-out period
Forth 1 One tablet (25-mg dose) of agomelatine test formulation
2 One tablet (25-mg dose) of agomelatine reference formulation
Fang Tang et al.74for the log-transformed ratios of AUC and Cmax of 7-desmethyl-
agomelatine and 3-hydroxy-agomelatine were within the bioequi-
valence range of ABE method. The sample size was calculated by
the within-subject variability (37.8%) of 3-hydroxy-agomelatine
from pre-experiment as follows33:
n¼ tα þ tβ
 
σd=δ
 2 ð8Þ
where tα is t value of the α inspection standards, tβ is the type II
error rate. δ is the requirements of discrimination, and σd is the
within-subject variability. As tα¼1.6449, tβ¼1.2816, δ¼0.2,
σd¼0.378, the sample size used was n¼31.
Based on the above, a minimum of 32 subjects were required.
Taking into account the test management and lost cases, 44
subjects were enrolled in the four-way crossover study.
Forty-four healthy Chinese male volunteers aged 18–40 years
with body mass indices (BMI) between 19 and 25 kg/m2 were
assessed for inclusion in the study. As females can be inﬂuenced
by additional variables such as menstruation and pregnancy, the
guidelines of the Chinese State Food and Drug Administration
(SFDA) generally recommend selecting healthy males for bioe-
quivalence studies32. Subjects were judged to be eligible for the
study when no clinically signiﬁcant abnormal ﬁndings existed on a
complete medical examination. The exam included medical
history, physical examination, 12-lead electrocardiogram, hema-
tology, blood biochemistry and urinalysis.
2.3. Blood sampling
Blood samples (5 mL) were collected from a suitable forearm vein
into anticoagulant tube by an indwelling catheter at the following
time point: 0 (before administration), 0.25, 0.5, 0.75, 1.0, 1.5, 2.0,
2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0 and 8.0 h after drug administration.
After washout and administration of the alternate formulation,
blood samples were drawn and analyzed in the same way.
2.4. Tolerability assessments
Subjects were carefully monitored by vital signs (sitting blood
pressure, heart rate, breathing rate, and oral body temperature),
clinical laboratory tests (hematology, blood biochemistry, and
urinalysis), 12-lead ECGs, and physical examinations at baseline
and at the end of each study period. National Cancer Institute
Common Toxicity Criteria for Adverse Events version 3.0 was
used to describe and grade all toxicities and adverse events. Therelationship of adverse events to study drug was documented by
the investigator as unrelated or unlikely, possibly, probably, or
deﬁnitely related.2.5. Pharmacokinetic evaluations
An LC–MS/MS validated method for the simultaneous determina-
tions of agomelatine, 3-hydroxy-agomelatine and 7-desmethyl-
agomelatine concentrations in human plasma. The analytes were
quantiﬁed by use of phenacetin as the internal standard. The
plasma sample clean-up procedure was performed by liquid-liquid
extraction. Aliquots (5 μL) were injected onto the analytical
column (Phenomenex ODS3, 150 mm 4.6 mm, 5 μm, USA).
The mobile phase consisted of methanol and formic acid aqueous
solution (20%) within 5 mmol/L ammonium formate (70:30, v/v)
was delivered with a ﬂow rate of 0.8 mL/min, with a run time of
approximately 7 min. Positively charged ions, created at atmo-
spheric pressure, were transferred to an Agilent 6460 triple-
quadrupole LC–MS (Aligent, USA). The transitions for agomela-
tine were selected from m/z 244.1-185.1, 3-hydroxy-agomelatine
from m/z 260.1-201.1, 7-desmethyl-agomelatine from m/z
230.1-171.1, and the internal standard from m/z 180.1-110.1.2.6. Pharmacokinetic analysis
A non-compartmental analysis was used to determine the pharma-
cokinetic parameters using WinNonlin 6.1. Cmax and Tmax were
obtained directly from the plasma concentration-time curves. The
AUC0–t was calculated according to the trapezoidal rule
34.
AUC0–1 was calculated as follows:
AUC01 ¼AUC0t þ Ct=ke ð9Þ
where Ct was the last measured concentration at time t, and ke was
the terminal elimination rate constant estimated by log-linear
regression analysis of data visually assessed to be a terminal
log-linear phase. At least 3 points were used for estimation of ke.
The apparent terminal elimination t1/2 was calculated as follows:
t1=2 ¼ 0:693=ke ð10Þ
Intra-individual variability for the considered pharmacokinetic
parameters was assessed by CV(%).
Figure 1 Plasma concentration-time curves of (A) agomelatine, (B) 3-hydroxy-agomelatine and (C) 7-desmehyl-agomelatine following a single
25-mg oral dose of a test (Chongqing FuAn Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd., Chongqing, China) or reference (Servier,
French) formulation of agomelatine 25-mg tablet in healthy fasted Chinese adult males. Data are expressed as Mean (SD), n¼44.
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To test the bioequivalence of the formulations, ANOVA was
performed on log-transformed Cmax, AUC0–t and AUC0–1. The
nonparametric signed rank test was used to complete the Tmax for
the 2 formulations. Pr0.05 was considered statistically signiﬁ-
cant. The ratios of the log-transformed Cmax, AUC0–t and AUC0–1
of parent agomelatine, 3-hydroxy-agomelatine and 7-desmethyl-
agomelatine for both formulations were calculated, and 90% CIs
were obtained. The probability of exceeding the limits of
acceptance was obtained by two 1-side t tests. The 2 formulations
were considered bioequivalent if the 90% CIs of the parent
agomelatine of two formulations ratios of AUC and Cmax were
within the limits according to RSABE method shows below:
Bioequivalence limits; upper; lower¼ e70:223σWR=σW0 ð11Þ
For 3-hydroxy-agomelatine and 7-desmethyl-agomelatine, the
test/reference ratios of AUC were within the predetermined
bioequivalence range of 0.80 to 1.25 and Cmax ratios were within
0.75–1.33, according to the guidelines of the SFDA of the
China32.
The bioequivalence assessment of the parent drug agomelatine
was an essential goal of the present study. Evaluation of the
bioequivalence of the two metabolites was considered as possibly
supportive evidence for the bioequivalence of the parent drug.3. Results
A total of 44 male subjects were enrolled in the study. Index, mean
(range): age, 22.8 (2.5) years (range, 19–28 years); height, 170
(10) cm (range, 157–181 cm); weight, 60.5 (6.3) kg (range,
51–74 kg); BMI, 20.7 (1.6) kg/m2 (range, 19.0–24.0 kg/m2). Each
subject received the test formulation and the reference formulation
twice, respectively. All volunteers completed the study.
3.1. Tolerability
There were no protocol violations or serious adverse events
observed in the study. Twenty subjects experienced a total of 37
mild adverse events in this four-way crossover study. The most
frequently recorded were somnolence (17), dizziness (6), insomnia
(6), epigastric pain (1). Somnolence, dizziness and insomnia were
considered to be deﬁnitely related to the study treatment, and
epigastric pain was considered to be probably related to the studymedication. There were no withdrawals from the study due to
adverse events.
3.2. Method validation
The calibration curves for agomelatine, 7-desmethyl-agomel-
atine and 3-hydroxy-agomelatine were linear over the conce-
ntration ranges of 0.0457–100 μg/L, 0.1372–300 μg/L and
0.4572–1000 μg/L in human plasma, respectively. The mean
regression equation of the calibration curve for agomelatine was
Y¼0.1188X–0.0005 (r2¼0.9962), for 7-desmethyl-agomelatine
was Y¼0.0734X–0.0003 (r2¼0.9975), and for 3-hydroxy-
agomelatine is Y¼0.0543X–0.0007 (r2¼0.9978) with lower limits
of quantitation being 0.0457, 0.1372 and 0.4572 μg/L, respec-
tively. Precision values were all o15%, and accuracy was
between 85% and 115%. Technically, the assay for the determina-
tion of agomelatine and its metabolites from human plasma was
highly reproducible, sensitive, and accurate method.
3.3. Pharmacokinetic properties
Following single 25-mg oral doses of the test and reference formula-
tions, the mean plasma concentration–time curve of agomelatine,
3-hydroxy-agomelatine and 7-desmesthyl-agomelatine are shown in
Fig. 1A–C, respectively. Mean pharmacokinetic parameters (AUC0–t,
AUC0–1, Cmax, Tmax, and t1/2) and CV(%) are summarized in Table 2.
For the parent agomelatine, no period or sequence effects were
detected for any pharmacokinetics properties on ANOVA. A
signiﬁcant subject effect was observed for AUC0–t, AUC0–1,
Cmax. There were no signiﬁcant differences between the two
formulations in regard to AUC0–t, AUC0–1, Cmax or t1/2 by two
1-side t tests, with the exception of Tmax (1.44 [0.75] h for the test
formulation and 1.22 [0.86] h for the reference formulation
(Po0.05 by Mann–Whitney U test). For the metabolite 3-
hydroxy-agomelatine and 7-desmethyl-agomelatine, no period,
formulation, or sequence effects were observed for any pharma-
cokinetic properties by ANOVA, and there were no signiﬁcant
differences between the two formulations in AUC0–t, AUC0–1,
Cmax by two 1-side t test or in Tmax by Mann–Whitney U test.
3.4. Bioequivalence evaluation
The 90% CIs of the ratios (T/R) for the log-transformed AUC0–t,
AUC0–1, Cmax are listed in Table 3. There were no signiﬁcant
differences between the test and reference formulations. The 90%
Table 2 Pharmacokinetic parameters and CV (%) of agomelatine, 3-hydroxy-agomelatine and 7-desmethyl-agomelatine after a single 25-
mg oral dose of a test or a reference formulation of agomelatine 25-mg tablet in healthy fasted Chinese adult males.
Parameter Agomelatine 3-Hydroxy-agomelatine 7-Desmethyl-agomelatine
Test Reference Test Reference Test Reference
AUC0–t (μg  h/L) 8.59 (10.17) 7.99 (10.15) 88.30 (31.81) 84.44 (32.49) 5.75 (2.64) 5.34 (2.38)
CV (%) 54.1 60.1 14.4 23.7 24.2 26.1
AUC0–1 (μg  h/L) 8.72 (10.16) 8.31 (10.23) 89.78 (32.27) 86.11 (33.06) 6.16 (2.76) 5.76 (2.51)
CV (%) 52.6 54.7 14.4 23.4 23.1 25.1
Cmax (μg  h/L) 7.55 (10.11) 5.74 (6.91) 50.09 (25.45) 43.30 (22.45) 4.43 (3.04) 3.77 (2.44)
CV (%) 84.4 80.0 43.9 42.0 53.5 46.7
Tmax (h) 1.14 (0.75) 1.22 (0.86) 1.13 (0.72) 1.25 (0.81) 1.07 (0.72) 1.23 (0.80)
t1/2 (h) 1.24 (1.40) 1.58 (1.32) 1.24 (0.24) 1.29 (0.26) 1.55 (1.97) 1.47 (0.92)
Data are expressed as Mean (SD), unless otherwise speciﬁed; n¼44.
Table 3 Comparison of 90% CIs of natural log(ln)-trans-
formed parameters of agomelatine, 3-hydroxy-agomelatine and
7-desmethyl-agomelatine for a test or reference formulation of
agomelatine 25-mg tablet after a single 25-mg oral dose in
healthy fasted Chinese adult males (n¼44).
Parameter Ratio 90% CI Power
Agomelatine
lnCmax 1.21 1.04–1.40 0.808
lnAUC0–t 1.12 1.01–1.24 0.978
lnAUC0–1 1.07 0.98–1.18 0.989
3-Hydropxy-agomelatine
lnCmax 1.14 1.06–1.23 0.999
lnAUC0–t 1.05 1.02–1.10 1.000
lnAUC0–1 1.05 1.02–1.09 1.000
7-Desmethyl-agomelatine
lnCmax 1.14 1.05–1.25 0.991
lnAUC0–t 1.07 1.02–1.12 1.000
lnAUC0–1 1.06 1.02–1.11 1.000
Fang Tang et al.76CIs for natural log-transformed ratios of Cmax, AUC0–t, AUC0–1
of agomelatine (104.42–139.86, 101.33–123.83, and 97.90–
117.94, respectively) were within the RSABE acceptance limits
(8.99%–204.13%, 59.48%–170.99%, 61.38%–162.91% for Cmax,
AUC0–t and AUC0–1, respectively). The metabolites 3-hydroxy-
agomelatine and 7-desmethyl-agomelatine were within the
predetermined regulatory 90% CI ranges for bioequivalence
(80%–125% for AUC0–t and AUC0–1, 75–133% for Cmax for
the T/R ratio).4. Discussion
According to US FDA guidelines35, only the parent compound
released from the formulation rather than the metabolite is
generally recommended for bioequivalence studies. However,
when a metabolite contributes meaningfully to the drug's pharma-
cologic effects or when a parent compound is difﬁcult to analyze
in plasma, metabolite quantiﬁcation is also recommended.
Although the pharmacokinetic parameters of agomelatine itself
are the most essential criteria for bioequivalence evaluation,
3-hydroxy-agomelatine and 7-desmethyl-agomelatine were
assessed in the present study to provide supporting evidence.The median values of Tmax for 3-hydroxy-agomelatine and 7-
desmethyl-agomelatine conﬁrmed the rapid disappearance of the
parent compound which was comparable between the two
formulations.
The FDA has recommended the RSABE approach to evaluate
the bioequivalence of highly variable drugs (e.g., agomelatine).
Accordingly, the acceptance limits for such a study is to be scaled
to the variability of the reference formulation. In the present study,
we used the RSABE approach to assess the bioequivalence of two
formulations of parent compounds for the ﬁrst time in Chinese
healthy male subjects. The standard criteria were used to evaluate
the bioequivalence of the test formulation and the reference
formulation, along with studies of the metabolites 3-hydroxy-
agomelatine and 7-desmethyl-agomelatine.
The aim of this study was to apply the RSABE approach to
evaluate the bioequivalence of 2 formulations of agomelatine, a
drug with highly variable kinetics, and to investigate the pharma-
cokinetic properties of agomelatine in Chinese healthy male
subjects. There are a few reports in the literature on the pharma-
cokinetics of agomelatine in Chinese population. Pei et al.14
investigated the CV(%) of agomelatine in 16 Chinese healthy male
volunteers and showed signiﬁcant ethnic differences between
Chinese and Caucasian subjects in Cmax and AUC0–t whereas no
ethnic differences in Tmax or t1/2 were found. Less obvious ﬁrst-pass
effects in Chinese subjects may partially account for why both Cmax
and AUC of Chinese males were much higher than those of
Caucasian males. In this study, the mean (SD) agomelatine and its
metabolites AUC0–t, Tmax, and Cmax for Chinese subjects (summar-
ized in Table 3) are presented for the ﬁrst time.
The 90% CIs of the test/reference ratios of Cmax, AUC0–t,
AUC0–1 for agomelatine and metabolites were all located within
RASBE and the standard criteria range, respectively. The %CV of
the main pharmacokinetic parameters of agomelatine and metabo-
lites varied greatly. The large inter-subject variability in pharma-
cokinetic behavior observed in our study was consistent with the
previous literature in other populations7. Agomelatine is rapidly
absorbed from the gastrointestinal tract and immediately trans-
ported to the liver, where it is extensively metabolized by
cytochrome P450 (CYP) isoenzymes CYP1A1, CYP1A2 and
CYP2C936. 7-Desmethyl-agomelatine and 3-hydroxy-agomelatine
were identiﬁed as the two metabolites of agomelatine, which have
less activity than the parent drug, and no signiﬁcant differences
of absorption and metabolism were found among agomelatine,
3-hydroxy-agomelatine and 7-desmethyl-agomelatine for the two
formulations in 44 subjects.
Implementation of a reference-scaled average bioequivalence approach 77The present study had several limitations that should be
considered. The pharmacokinetic data of this study were obtained
only from Chinese healthy males who were administered a single
dose. Therefore, the pharmacokinetics might be different in other
targeted populations or after other dosage regimens.5. Conclusions
The RSABE approach was successfully applied to evaluate the
bioequivalence of two formulations of the highly variable drug
agomlatine in Chinese male volunteers. This study found that the
test and reference formulations of aogmelatine 25-mg tablet met
the regulatory deﬁnition.
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